DE60027564D1 - Tek-antagonisten - Google Patents
Tek-antagonistenInfo
- Publication number
- DE60027564D1 DE60027564D1 DE60027564T DE60027564T DE60027564D1 DE 60027564 D1 DE60027564 D1 DE 60027564D1 DE 60027564 T DE60027564 T DE 60027564T DE 60027564 T DE60027564 T DE 60027564T DE 60027564 D1 DE60027564 D1 DE 60027564D1
- Authority
- DE
- Germany
- Prior art keywords
- tek antagonists
- methods
- tek
- antagonists
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13788999P | 1999-06-07 | 1999-06-07 | |
US137889P | 1999-06-07 | ||
PCT/US2000/015706 WO2000075323A1 (en) | 1999-06-07 | 2000-06-07 | Tek antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
DE60027564D1 true DE60027564D1 (de) | 2006-06-01 |
DE60027564T2 DE60027564T2 (de) | 2007-05-10 |
DE60027564T3 DE60027564T3 (de) | 2009-07-23 |
Family
ID=22479496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60027564T Expired - Lifetime DE60027564T3 (de) | 1999-06-07 | 2000-06-07 | Tek-antagonisten |
Country Status (14)
Country | Link |
---|---|
US (2) | US6413932B1 (de) |
EP (1) | EP1187918B9 (de) |
JP (1) | JP4587626B2 (de) |
AT (1) | ATE324444T1 (de) |
AU (1) | AU783960B2 (de) |
CA (1) | CA2374851A1 (de) |
CY (1) | CY1105078T1 (de) |
DE (1) | DE60027564T3 (de) |
DK (1) | DK1187918T4 (de) |
ES (1) | ES2262518T5 (de) |
IL (2) | IL146482A0 (de) |
NZ (1) | NZ516258A (de) |
PT (1) | PT1187918E (de) |
WO (1) | WO2000075323A1 (de) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU782067B2 (en) | 1999-12-20 | 2005-06-30 | Immunex Corporation | TWEAK receptor |
AU2002339863A1 (en) * | 2001-08-31 | 2003-03-18 | Abmaxis, Inc. | Multivalent protein conjugate with multiple ligand-binding domains of receptors |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
CN1315536C (zh) * | 2002-09-13 | 2007-05-16 | 李进 | 肿瘤抗原疫苗及其制备方法和疫苗组合物 |
AU2004265226A1 (en) * | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Intron fusion proteins, and methods of identifying and using same |
RS53476B (en) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Hepatocyte Growth Factor Binders |
WO2005113596A2 (en) * | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
CA2571752A1 (en) * | 2004-06-25 | 2006-01-12 | Licentia, Ltd. | Tie receptor and tie ligand materials and methods for modulating female fertility |
US7507748B2 (en) * | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
US20080119367A1 (en) * | 2004-12-17 | 2008-05-22 | Mayo Foundation For Medical Education And Research | Prognosis of Renal Cell Carcinoma |
US7973140B2 (en) * | 2004-12-21 | 2011-07-05 | Medimmune Limited | Antibodies directed to angiopoietin-2 and uses thereof |
US20090170769A1 (en) * | 2005-05-13 | 2009-07-02 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
NO2188313T3 (de) | 2007-08-21 | 2018-03-31 | ||
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
NZ586701A (en) | 2008-01-03 | 2013-07-26 | Scripps Research Inst | Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2) |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
EP2247305A4 (de) | 2008-01-28 | 2012-11-14 | Medimmune Ltd | Stabilisierte angiopoietin-2-antikörper und verwendungen davon |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
EP2937349B1 (de) | 2011-03-23 | 2016-12-28 | Amgen Inc. | Fusionierte tricyclische duale inhibitoren von cdk 4/6 und flt3 |
ES2704038T3 (es) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Complejos multiespecíficos multivalentes y monovalentes y sus usos |
US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
EP3415533A1 (de) * | 2011-08-19 | 2018-12-19 | Regeneron Pharmaceuticals, Inc. | Anti-tie2-antikörper und verwendungen davon |
US10316105B2 (en) | 2011-08-19 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Anti-TIE2 antibodies and uses thereof |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
GB201223053D0 (en) | 2012-12-20 | 2013-02-06 | Medical Res Council | Receptor |
BR112015023752B1 (pt) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
CN109069639B (zh) | 2016-03-08 | 2022-07-08 | 詹森生物科技公司 | Gitr抗体、方法及用途 |
UA124474C2 (uk) | 2016-12-22 | 2021-09-22 | Емджен Інк. | БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
EP3679040B1 (de) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitoren von kras g12c und verfahren zur verwendung davon |
WO2019213526A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
EP3788038B1 (de) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Kras-g12c-inhibitoren und verfahren zu deren verwendung |
AU2019265822B2 (en) | 2018-05-10 | 2024-07-18 | Amgen Inc. | KRAS G12C inhibitors for the treatment of cancer |
AU2019278998B2 (en) | 2018-06-01 | 2023-11-09 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
MA52780A (fr) | 2018-06-11 | 2021-04-14 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
CN108888756A (zh) * | 2018-07-25 | 2018-11-27 | 韩曙 | C16多肽和血管生成素Ang1的应用和应用二者的药物 |
JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
MX2021005700A (es) | 2018-11-19 | 2021-07-07 | Amgen Inc | Inhibidores de kras g12c y metodos de uso de los mismos. |
MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
CA3123227A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
EP3898592A1 (de) | 2018-12-20 | 2021-10-27 | Amgen Inc. | Als kif18a-inhibitoren verwendbare heteroarylamide |
MA54550A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
US20230148450A9 (en) | 2019-03-01 | 2023-05-11 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
EP3738593A1 (de) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosierung von kras-inhibitor zur behandlung von krebserkrankungen |
CA3140392A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
BR112021026376A2 (pt) * | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
CA3147276A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
CA3146693A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
MX2022001181A (es) | 2019-08-02 | 2022-02-22 | Amgen Inc | Inhibidores de kif18a. |
US20220402916A1 (en) | 2019-09-18 | 2022-12-22 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
AU2020372881A1 (en) | 2019-10-28 | 2022-06-09 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
US20230023023A1 (en) | 2019-10-31 | 2023-01-26 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
MX2022005360A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
JP2022553858A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
CR20220240A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
BR112022008858A2 (pt) | 2019-11-08 | 2022-09-06 | Revolution Medicines Inc | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer |
JP2023501528A (ja) | 2019-11-14 | 2023-01-18 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の改善された合成 |
TW202132271A (zh) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Kras g12c抑制劑化合物之改善的合成 |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
KR20220124768A (ko) | 2020-01-07 | 2022-09-14 | 레볼루션 메디슨즈, 인크. | Shp2 억제제 투여 및 암 치료방법 |
US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
US20230181536A1 (en) | 2020-04-24 | 2023-06-15 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
WO2022014640A1 (ja) | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ |
KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
JP2023541916A (ja) | 2020-09-15 | 2023-10-04 | レボリューション メディシンズ インコーポレイテッド | がんの治療における、ras阻害剤としてのインドール誘導体 |
CA3203111A1 (en) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Sos1 inhibitors and uses thereof |
BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
EP4334321A1 (de) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras-inhibitoren |
PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
CN117769554A (zh) | 2021-05-28 | 2024-03-26 | 大鹏药品工业株式会社 | Kras突变蛋白的小分子抑制剂 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (de) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazinverbindungen als shp2-inhibitoren |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1411092A (en) * | 1991-01-31 | 1992-09-07 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
WO1993014124A1 (en) | 1992-01-09 | 1993-07-22 | Helsinki University Holding, Ltd. | Tie, a novel endothelial cell receptor tyrosine kinase |
US5955291A (en) | 1992-01-09 | 1999-09-21 | Alitalo; Kari | Antibodies recognizing tie receptor tyrosine kinase and uses thereof |
AU4651893A (en) | 1992-06-26 | 1994-01-24 | Immunex Corporation | Novel tyrosine kinase |
US5681714A (en) | 1992-07-30 | 1997-10-28 | Mount Sinai Hospital Corporation | Nucleic acid encoding tek receptor tyrosine kinase |
JPH06315382A (ja) | 1993-05-06 | 1994-11-15 | Toshio Suda | Tie−2受容体をコードするdna及びtie−2受容体 |
WO1995013387A1 (en) | 1993-11-12 | 1995-05-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tie-2, a novel receptor tyrosine kinase |
AUPM379494A0 (en) * | 1994-02-10 | 1994-03-03 | Ludwig Institute For Cancer Research | Immunointeractive molecules - ii |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
EP0854185A3 (de) | 1994-12-23 | 1998-10-21 | Ludwig Institute For Cancer Research | Rezeptor-Proteine zu Bestimmungszwecke und Liganden |
AU715621B2 (en) | 1995-04-06 | 2000-02-03 | Regeneron Pharmaceuticals, Inc. | TIE-2 ligands, methods of making and uses thereof |
US6033903A (en) * | 1995-06-02 | 2000-03-07 | Applied Research Systems, ARS Holding N.V. | Method of expressing and secreting soluble extracellular domains of human gonadotropin hormone receptors |
EP0965637B1 (de) * | 1996-05-02 | 2005-07-20 | Mochida Pharmaceutical Co., Ltd. | Fas ANTIGEN-DERIVATE |
WO1998018914A1 (en) | 1996-10-31 | 1998-05-07 | Duke University | Soluble tie2 receptor |
US6376653B1 (en) | 1998-09-28 | 2002-04-23 | Smithkline Beecham Plc | Tie2 antagonist antibodies |
-
2000
- 2000-06-07 DE DE60027564T patent/DE60027564T3/de not_active Expired - Lifetime
- 2000-06-07 ES ES00938207T patent/ES2262518T5/es not_active Expired - Lifetime
- 2000-06-07 EP EP00938207A patent/EP1187918B9/de not_active Expired - Lifetime
- 2000-06-07 NZ NZ516258A patent/NZ516258A/xx not_active IP Right Cessation
- 2000-06-07 IL IL14648200A patent/IL146482A0/xx unknown
- 2000-06-07 CA CA002374851A patent/CA2374851A1/en not_active Abandoned
- 2000-06-07 US US09/590,656 patent/US6413932B1/en not_active Expired - Fee Related
- 2000-06-07 AT AT00938207T patent/ATE324444T1/de not_active IP Right Cessation
- 2000-06-07 AU AU53282/00A patent/AU783960B2/en not_active Ceased
- 2000-06-07 PT PT00938207T patent/PT1187918E/pt unknown
- 2000-06-07 WO PCT/US2000/015706 patent/WO2000075323A1/en active IP Right Grant
- 2000-06-07 DK DK00938207T patent/DK1187918T4/da active
- 2000-06-07 JP JP2001502586A patent/JP4587626B2/ja not_active Expired - Fee Related
-
2001
- 2001-11-14 IL IL146482A patent/IL146482A/en not_active IP Right Cessation
-
2006
- 2006-05-02 US US11/416,613 patent/US20070025993A1/en not_active Abandoned
- 2006-07-07 CY CY20061100953T patent/CY1105078T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000075323A1 (en) | 2000-12-14 |
NZ516258A (en) | 2004-02-27 |
EP1187918A1 (de) | 2002-03-20 |
JP2003501090A (ja) | 2003-01-14 |
IL146482A (en) | 2010-11-30 |
DE60027564T3 (de) | 2009-07-23 |
AU5328200A (en) | 2000-12-28 |
EP1187918B9 (de) | 2009-08-19 |
ES2262518T3 (es) | 2006-12-01 |
IL146482A0 (en) | 2002-07-25 |
EP1187918B1 (de) | 2006-04-26 |
CY1105078T1 (el) | 2009-11-04 |
ES2262518T5 (es) | 2009-05-08 |
US20070025993A1 (en) | 2007-02-01 |
DE60027564T2 (de) | 2007-05-10 |
PT1187918E (pt) | 2006-08-31 |
DK1187918T3 (da) | 2006-08-21 |
US6413932B1 (en) | 2002-07-02 |
CA2374851A1 (en) | 2000-12-14 |
ATE324444T1 (de) | 2006-05-15 |
AU783960B2 (en) | 2006-01-05 |
DK1187918T4 (da) | 2009-02-23 |
JP4587626B2 (ja) | 2010-11-24 |
EP1187918B2 (de) | 2009-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1187918T3 (da) | TEK-antagonister | |
NO20034056D0 (no) | Proliferative sykdommer | |
ATE293989T1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
CY1107074T1 (el) | Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης | |
HRP20080467A2 (en) | 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia | |
DK1202736T3 (da) | Nikotin i terapeutisk angiogenese og vasculogenese | |
NO20001598L (no) | Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser | |
WO2006015060A3 (en) | Isoindoline compounds and methods of their use | |
DE60231439D1 (de) | Mitotische kinesinhemmer | |
DE60234278D1 (de) | Mitotische kinesin-hemmer | |
MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
ATE333882T1 (de) | Zusammensetzungen zur hemmung der angiogenese | |
DE59708265D1 (de) | Neue in 6-position substituierte phenanthridine | |
ATE344031T1 (de) | Thrombopoietin-mimetika | |
IL153680A0 (en) | Aplidine derivatives and methods for the preparation thereof | |
PT1109571E (pt) | Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
DK1220852T3 (da) | Substituerede diazepaner | |
DE60108626D1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer | |
AP9801202A0 (en) | Atropisomers of 3-heteroaryl-4(3H)-quinazolinones. | |
DK1196442T3 (da) | VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
DK1185293T3 (da) | IL6RIL6-kimær til behandling af neurodegenerative sygdomme | |
BR0111785A (pt) | Composições e métodos para tratamento de candidìase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN |
|
8366 | Restricted maintained after opposition proceedings |